Novo Nordisk Goldman target lift, shares consolidate near Copenhagen high
27.06.2026 - 14:57:31 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-27, 14:57.
Novo Nordisk (DK0060534915) sits close to a fresh price mark on Nasdaq Copenhagen after Goldman Sachs lifted its price target to 310 Danish kroner while reiterating a Neutral rating, according to recent analyst notes on the OMX Copenhagen 25 member.Marketscreener analyst update summary
What Goldman Sachs changed
On June 26 Goldman Sachs raised its Novo Nordisk price target from 305 to 310 Danish kroner and kept the recommendation at Neutral, signaling a cautious stance despite the incremental target lift.German Marketscreener note on Goldman’s move
The update comes as the Danish drug maker remains a heavy-weight constituent in the STOXX Europe 50 and STOXX Europe 600 indices, reflecting its sizeable market capitalization above 1 trillion kroner on Nasdaq Copenhagen.Hargreaves Lansdown key share data
How the wider consensus looks
Consensus data compiled by Marketscreener shows a mixed analyst picture for Novo Nordisk, with multiple houses including Deutsche Bank and Morningstar rating the stock Hold and target prices around the 290 to 343 kroner range, underscoring a balanced risk-reward assessment.Marketscreener consensus overview
Morningstar, for example, recently downgraded Novo Nordisk from Buy to Hold while confirming a 343 kroner target, pointing to robust fundamentals but a valuation that already reflects much of the growth in obesity therapies.Morningstar rating change reference
All news and analysis on the Novo Nordisk shares
Further company releases, analyst notes and price data on Novo Nordisk are available in the dedicated topic section and via the firm’s Investor Relations page.
The product behind the stock
Novo Nordisk generates a large portion of its revenue from GLP-1 based treatments such as the obesity drug Wegovy and diabetes therapy Ozempic, which are prescribed worldwide as part of chronic weight-management and blood-sugar control regimens.
Where the stock trades today
The Novo Nordisk shares (DK0060534915) last closed on June 26, 2026, on Nasdaq Copenhagen at 317.95 Danish kroner.
Novo Nordisk key share data
- Company: Novo Nordisk A/S
- ISIN: DK0060534915
- WKN: A3EU6F
- Ticker: NOVO B (Copenhagen), NVO (NYSE)
- Trading venue: Nasdaq Copenhagen
- Price (as of 2026-06-26, 16:00): 317.95 DKK
- Market cap: 1.07 trillion DKK (as of 2026-06-26)
- Sector / industry: Pharmaceuticals / Biotechnology
- Index membership: OMX Copenhagen 25, STOXX Europe 50, STOXX Europe 600
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities. All data are based on sources deemed reliable but cannot be guaranteed. Investors should perform their own research and consider professional advice before making investment decisions.
